Navigation Links
Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
Date:12/20/2010

SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that Gregory Papaz has joined Optimer as Senior Vice President of Commercial Operations.  Mr. Papaz will lead the preparations for the planned commercialization of fidaxomicin.  He brings with him more than thirty years of experience in the healthcare and pharmaceutical industry managing pharmaceutical sales teams.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"Greg comes to Optimer with best-in-class business experience in the hospital and specialty market segments combined with a proven record of recent successful new product introductions," said Pedro Lichtinger, Optimer's President and CEO. "Greg will build and lead our commercial organization in the United States and is ideally suited to lead a successful hospital launch for fidaxomicin."

Prior to joining Optimer, Mr. Papaz held the position of Rheumatology Sales Director, Commercial Marketing at Genentech where he was responsible for planning and launching Actemra®, a drug for rheumatoid arthritis. In this role, Mr. Papaz staffed a 130-person sales team which sold directly into hospitals, with direct contact to hospital pharmacies, physician leaders and hospital management. Prior to Genentech, he worked for Roche Pharma as the Anemia National Sales Director. Prior to Roche Pharma, Mr. Papaz was the Vice President, Cardiovascular Hospital Sales at Sanofi-Aventis.  While in this position, Greg merged and restructured the Sanofi hospital team with the Aventis Advanced Therapeutics team.  This resulted in the creation of the largest specialized sales force at Sanofi, as well as the largest hospital sales force in the U.S. pharma industry.  Consequently, Greg was involved in overseeing a team of approximately 850 hospital sales professionals, including 85 managers and 11 directors, and managed $2 billion in annual Lovenox® sales and the hospital portion of the $4 billion Plavix® business.  

Mr. Papaz began his career as a sales representative for Marion Laboratories and was quickly promoted into larger sales leadership roles over the next thirty years, including Vice President, Bone/CNS Sales, followed by Vice President, Oncology Sales at Aventis Pharmaceuticals prior to his position at Sanofi-Aventis. Mr. Papaz received his MBA from the Johnson School of Business at Cornell University. He holds a BS in Hospital and Healthcare Administration from Providence College.  

About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin).  Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  The Company has submitted an NDA to the FDA, and filed a MAA with the EMA (European Medicines Agency) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-Looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the potential approval and commercial launch of fidaxomicin, Optimer's establishment of a commercial organization and the future roles and contributions of Mr. Papaz at Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product development efforts, the timing and status of regulatory filings, receipt of regulatory approvals, Optimer's ability to recruit and retain a commercial sales force, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
2. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
3. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
5. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
8. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
9. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
10. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
11. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “When the ... Lead Home” is the creation of published author Laura Weigel Douglas, an avid reader ... cat in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
Breaking Medicine News(10 mins):